124 related articles for article (PubMed ID: 445304)
1. Early diagnosis of ovarian cancer.
Popkin DR
Can Med Assoc J; 1979 May; 120(9):1106-8. PubMed ID: 445304
[TBL] [Abstract][Full Text] [Related]
2. [Comments on the paper by Schröck et al., The simultaneous determination of Ca 125 and D-dimer in plasma and ascitic fluid in ovarian cancer].
Mezger J
Onkologie; 1986 Feb; 9(1):10. PubMed ID: 3523340
[No Abstract] [Full Text] [Related]
3. Fibrin degradation products and the diagnosis of ovarian carcinoma.
Anstey JT; Blythe JG
Obstet Gynecol; 1978 Nov; 52(5):605-8. PubMed ID: 724180
[TBL] [Abstract][Full Text] [Related]
4. [Comparative study of 3 markers in ovarian cancer: CA 125, CA 19,9 and CEA].
Vigné E; Krebs B; Khater R; Mira R; Boublil JL; Jourlait A; Frenay M; Namer M
J Gynecol Obstet Biol Reprod (Paris); 1986; 15(5):609-13. PubMed ID: 3463621
[TBL] [Abstract][Full Text] [Related]
5. The preoperative diagnosis of malignancy of ovarian cysts.
Tropé C
Neoplasma; 1981; 28(1):117-21. PubMed ID: 7279055
[TBL] [Abstract][Full Text] [Related]
6. [Markerfunction of crosslinked fibrin derivatives in ascitic fluid from patients with ovarian cancer: a comparison with ascitic fluid in liver cirrhosis].
Graeff H; Klaubert W; Klaubert E; Gollwitzer R; von Hugo R; Hafter R
Geburtshilfe Frauenheilkd; 1983 Jun; 43 Suppl 1():42-6. PubMed ID: 6555132
[TBL] [Abstract][Full Text] [Related]
7. The value of epithelial membrane antigen in the diagnosis of ovarian tumors.
Fujimoto I; Hirai Y; Hasumi K; Masubuchi K; Osamura Y
Acta Cytol; 1990; 34(4):549-54. PubMed ID: 1695804
[TBL] [Abstract][Full Text] [Related]
8. [Serum levels of CA 125, CA 19-9, TPA, CEA and CA 50: useful evaluation parameters in the diagnosis of ovarian cancer].
Gadducci A; Ferdeghini M; Bartolini T; Facchini V; Bianchi R; Fioretti P
Ann Ostet Ginecol Med Perinat; 1986; 107(4):193-9. PubMed ID: 3467641
[No Abstract] [Full Text] [Related]
9. [CEA determination in aspired fluid of cystic ovarian tumors and ovarian cysts and in ascites and serum samples of patients with ovarian tumors].
Kunze M; Büttner HH; Strache RR; Voss P; Briese V; Schrodt U
Zentralbl Gynakol; 1988; 110(16):1006-12. PubMed ID: 3188713
[TBL] [Abstract][Full Text] [Related]
10. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
11. [Immunochemical study of antigens in the ascitic fluid of patients with ovarian cancer].
Sergeeva NS; Vasil'ev MIu; Avdeev GI
Eksp Onkol; 1986; 8(4):37-40. PubMed ID: 3757883
[TBL] [Abstract][Full Text] [Related]
12. Peritoneal fluid profiles.
McGowan L
Natl Cancer Inst Monogr; 1975 Oct; 42():75-9. PubMed ID: 1234638
[TBL] [Abstract][Full Text] [Related]
13. Serum CA-125 screening for ovarian cancer in patients with dermatomyositis.
Whitmore SE; Anhalt GJ; Provost TT; Zacur HA; Hamper UM; Helzlsouer KJ; Rosenshein NB
Gynecol Oncol; 1997 May; 65(2):241-4. PubMed ID: 9159332
[TBL] [Abstract][Full Text] [Related]
14. [Significance of CA 125 antigen levels in patients with ovarian cancer].
Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
[TBL] [Abstract][Full Text] [Related]
15. [Molecular markers of ovarian carcinoma].
Dobryszycka W
Postepy Hig Med Dosw; 2000; 54(4):495-518. PubMed ID: 11016269
[TBL] [Abstract][Full Text] [Related]
16. [The present status of tumor markers in malignant ovarian tumor].
Nishimura H; Miyoshi T; Hamai J; Miyahara K
Gan No Rinsho; 1985 May; 31(6 Suppl):589-93. PubMed ID: 2411960
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer.
Crombach G; Zippel HH; Würz H
Cancer Detect Prev; 1985; 8(1-2):135-9. PubMed ID: 3864535
[TBL] [Abstract][Full Text] [Related]
18. [Cancer of the ovary: the usefulness of Cul-de-sac aspiration and the level of carcino-embryonic antigen in the peritoneal fluid].
Zylberberg B; Salat-Baroux J; Ravina JH; Demarcourt V; Dormont D
J Gynecol Obstet Biol Reprod (Paris); 1982; 11(3):365-70. PubMed ID: 7119382
[TBL] [Abstract][Full Text] [Related]
19. Serum fibrinogen/fibrin degradation products in patients with ovarian carcinoma.
Lalos O; Frankendal B; Rudolphi O
Ann Chir Gynaecol; 1977; 66(3):131-134. PubMed ID: 327909
[TBL] [Abstract][Full Text] [Related]
20. [Distribution of one of the ascitic fluid antigens of ovarian cancer patients in malignant tumors of the stomach and intestines].
Sergeeva NS; Vasil'ev MIu; Kovalenko TI; Sokolova NV; Avdeev GI
Eksp Onkol; 1989; 11(2):35-7. PubMed ID: 2661204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
